Feed / STRO

Sutro Biopharma, Inc.

STRO

Healthcare · 21.86 -21.9% today

Dominant mover · weak group confirmationMarket checked 19 Aug, 15:55 GMT-4

Jodie situation report

STRO dominates a concentrated Clinical-Stage Biotech move.

STRO accounts for 46.4% of the group's measured movement across 2.0 effective names. raw member direction is mixed; 1 of 2 session-normalized paths align to the upside. Capital-flow agreement is 38%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

Session-normalized 5m paths
Role in the moveDominant mover#2 of 2 by movement share
Group movement share46.4%Absolute path energy—not portfolio weight
Relative path-4.75%counter
Effective breadth2.0 / 2concentrated
Relative alignment1/2upside path · 1 counter-moving
Capital-flow agreement38%not yet clean
SEQUENCE READ

CAPR moved materially before STRO. STRO crossed its material path threshold at 11:15 ET, 75 minutes after the first measured mover.

EVIDENCE COVERAGE

2 of 2 members in Clinical-Stage Biotech are active. 0 of 8 disclosed connections are confirming.

What would change this read
  • At least 2 of 2 members remain active in the next snapshot.
  • Capital-flow agreement rises above 55%.
  • EWTX remains aligned with the group in the next market snapshot.

Invalidation: The live read weakens if participation falls to 1 of 2 members or fewer.

Watch this read

Who this business touches

The relationships behind STRO

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

PCVXVaxcyte, Inc.partnerMar 23, 2026 ▾

“Our total revenue to date has been generated principally from our collaboration and license agreements with BMS, Merck, Astellas, Vaxcyte, Ipsen, EMD Serono, BioNova, and Tasly, and to a lesser extent, from manufacturing, supply and services and materials we…”

BMYBristol-Myers Squibb CompanypartnerMar 23, 2026 ▾

“Enabled through our proprietary XpressCF ® and XpressCF+ ® platforms, we have entered into multitarget, product-focused collaborations with leading pharmaceutical and biotechnology companies in the field of oncology, including an immunostimulatory ADCs collab…”

MRKMerck & Company, Inc.partnerMar 23, 2026 ▾

“Enabled through our proprietary XpressCF ® and XpressCF+ ® platforms, we have entered into multitarget, product-focused collaborations with leading pharmaceutical and biotechnology companies in the field of oncology, including an immunostimulatory ADCs collab…”

Filing peers

AKTXZYMECBIO

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 11 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

STRO is currently a Leader in the organic co-movement group Clinical-Stage Biotech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.